Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumor necrosis factor-alpha antagonist
Given issues with the stability of the sponsor's probabilistic analysis (i.e., wide variation in the incremental cost-effectiveness ratios [ICERs] at each model run due in part to the wide credible intervals within the sponsor's submitted network meta-analysis [NMA]), CADTH conducted reana...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references